Avivagen Stock Today

Avivagen is selling for under 0.005 as of the 23rd of July 2024; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.005. Equity ratings for Avivagen are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of June 2024 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Valuation Profit Patterns
Check how we calculate scores

Avivagen Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Avivagen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Avivagen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President InnovationJames Nickerson
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors)
Avivagen's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Avivagen's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
Avivagen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Avivagen's financial leverage. It provides some insight into what part of Avivagen's total assets is financed by creditors.
Liquidity
Avivagen cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Avivagen has accumulated 6.09 M in total debt. Avivagen has a current ratio of 2.87, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Avivagen until it has trouble settling it off, either with new capital or with free cash flow. So, Avivagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Avivagen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Avivagen to invest in growth at high rates of return. When we think about Avivagen's use of debt, we should always consider it together with cash and equity.

Net Income

(5.19 Million)
Avivagen (VIV) is traded on TSX Venture Exchange in Canada and employs 6 people. Avivagen is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 388.47 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Avivagen's market, we take the total number of its shares issued and multiply it by Avivagen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Avivagen classifies itself under Pharmaceuticals sector and is part of Health Care industry. The entity has 77.69 M outstanding shares of which 6.25 K shares are at this time shorted by private and institutional investors with about 7.08 days to cover all short positions. Avivagen has accumulated about 3.23 M in cash with (3.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Avivagen Probability Of Bankruptcy

Avivagen Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Avivagen market risk premium is the additional return an investor will receive from holding Avivagen long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Avivagen. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Avivagen's alpha and beta are two of the key measurements used to evaluate Avivagen's performance over the market, the standard measures of volatility play an important role as well.

Avivagen Stock Against Markets

Avivagen Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Avivagen stock to make a market-neutral strategy. Peer analysis of Avivagen could also be used in its relative valuation, which is a method of valuing Avivagen by comparing valuation metrics with similar companies.
 Risk & Return  Correlation

Avivagen Corporate Directors

Tracy BVSCDirector ManagerProfile
Drew BasekDirector of Investor RelationsProfile
Graham BurtonCo-Founder, Director of Commercialization Science and DirectorProfile
G AnthonyIndependent DirectorProfile

Additional Tools for Avivagen Stock Analysis

When running Avivagen's price analysis, check to measure Avivagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avivagen is operating at the current time. Most of Avivagen's value examination focuses on studying past and present price action to predict the probability of Avivagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avivagen's price. Additionally, you may evaluate how the addition of Avivagen to your portfolios can decrease your overall portfolio volatility.